Literature DB >> 20003989

Early-life stress and antidepressant treatment involve synaptic signaling and Erk kinases in a gene-environment model of depression.

Laura Musazzi1, Alessandra Mallei, Daniela Tardito, Susanne H M Gruber, Aram El Khoury, Giorgio Racagni, Aleksander A Mathé, Maurizio Popoli.   

Abstract

Stress has been shown to interact with genetic vulnerability in pathogenesis of psychiatric disorders. Here we investigated the outcome of interaction between genetic vulnerability and early-life stress, by employing a rodent model that combines an inherited trait of vulnerability in Flinders Sensitive Line (FSL) rats, with early-life stress (maternal separation). Basal differences in synaptic signaling between FSL rats and their controls were studied, as well as the consequences of early-life stress in adulthood, and their response to chronic antidepressant treatment (escitalopram). FSL rats showed basal differences in the activation of synapsin I and Erk1/2, as well as in alpha CaM kinase II/syntaxin-1 and alpha CaM kinase II/NMDA-receptor interactions in purified hippocampal synaptosomes. In addition, FSL rats displayed a blunted response of Erk-MAP kinases and other differences in the outcome of early-life stress in adulthood. Escitalopram treatment restored some but not all alterations observed in FSL rats after early-life stress. The marked alterations found in key regulators of presynaptic release/neurotransmission in the basal FSL rats, and as a result of early-life stress, suggest synaptic dysfunction. These results show that early gene-environment interaction may cause life-long synaptic changes affecting the course of depressive-like behavior and response to drugs. (c) 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20003989     DOI: 10.1016/j.jpsychires.2009.11.008

Source DB:  PubMed          Journal:  J Psychiatr Res        ISSN: 0022-3956            Impact factor:   4.791


  14 in total

1.  Maternal separation enhances object location memory and prevents exercise-induced MAPK/ERK signalling in adult Sprague-Dawley rats.

Authors:  Nokuthula Makena; Kishor Bugarith; Vivienne A Russell
Journal:  Metab Brain Dis       Date:  2012-04-03       Impact factor: 3.584

2.  Chronic escitalopram treatment restores spatial learning, monoamine levels, and hippocampal long-term potentiation in an animal model of depression.

Authors:  V Bhagya; B N Srikumar; T R Raju; B S Shankaranarayana Rao
Journal:  Psychopharmacology (Berl)       Date:  2010-11-04       Impact factor: 4.530

3.  Serotonergic signalling suppresses ataxin 3 aggregation and neurotoxicity in animal models of Machado-Joseph disease.

Authors:  Andreia Teixeira-Castro; Ana Jalles; Sofia Esteves; Soosung Kang; Liliana da Silva Santos; Anabela Silva-Fernandes; Mário F Neto; Renée M Brielmann; Carlos Bessa; Sara Duarte-Silva; Adriana Miranda; Stéphanie Oliveira; Andreia Neves-Carvalho; João Bessa; Teresa Summavielle; Richard B Silverman; Pedro Oliveira; Richard I Morimoto; Patrícia Maciel
Journal:  Brain       Date:  2015-09-15       Impact factor: 13.501

Review 4.  Gene-environment interactions: early life stress and risk for depressive and anxiety disorders.

Authors:  Nicole R Nugent; Audrey R Tyrka; Linda L Carpenter; Lawrence H Price
Journal:  Psychopharmacology (Berl)       Date:  2011-01-12       Impact factor: 4.530

Review 5.  Escitalopram, an antidepressant with an allosteric effect at the serotonin transporter--a review of current understanding of its mechanism of action.

Authors:  Huailing Zhong; Nasser Haddjeri; Connie Sánchez
Journal:  Psychopharmacology (Berl)       Date:  2011-09-08       Impact factor: 4.530

Review 6.  Targeting opioid dysregulation in depression for the development of novel therapeutics.

Authors:  Caroline A Browne; Irwin Lucki
Journal:  Pharmacol Ther       Date:  2019-04-30       Impact factor: 12.310

Review 7.  Agomelatine: mechanism of action and pharmacological profile in relation to antidepressant properties.

Authors:  B Guardiola-Lemaitre; C De Bodinat; P Delagrange; M J Millan; C Munoz; E Mocaër
Journal:  Br J Pharmacol       Date:  2014-08       Impact factor: 8.739

8.  Cannabinoids, Neurogenesis and Antidepressant Drugs: Is there a Link?

Authors:  Manoela Viar Fogaça; Ismael Galve-Roperh; Francisco Silveira Guimarães; Alline Cristina Campos
Journal:  Curr Neuropharmacol       Date:  2013-05       Impact factor: 7.363

9.  Altered functional protein networks in the prefrontal cortex and amygdala of victims of suicide.

Authors:  Katalin Adrienna Kékesi; Gábor Juhász; Attila Simor; Péter Gulyássy; Eva Mónika Szegő; Eva Hunyadi-Gulyás; Zsuzsanna Darula; Katalin F Medzihradszky; Miklós Palkovits; Botond Penke; András Czurkó
Journal:  PLoS One       Date:  2012-12-06       Impact factor: 3.240

Review 10.  Elucidating the Possible Role of FoxO in Depression.

Authors:  Tarapati Rana; Tapan Behl; Aayush Sehgal; Vineet Mehta; Sukhbir Singh; Neelam Sharma; Simona Bungau
Journal:  Neurochem Res       Date:  2021-06-01       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.